鞘內泵市場規模、佔有率和趨勢分析 |全球| 2026–2032年

2025年全球鞘內幫浦市場規模為3.5億美元。預計該市場將以0.4%的複合年成長率成長，到2032年達到約3.6億美元。

本報告重點在於用於將藥物直接輸送到脊髓腔以治療慢性難治性疼痛和痙攣的鞘內幫浦。報告定量分析了手術例數、銷量、平均售價、市場規模、成長率和企業市場占有率，包括截至2022年的歷史數據和截至2032年的預測數據。

預計在預測期內，鞘內泵市場將保持溫和成長，這主要得益於銷量的逐步成長，而銷量成長又受到人口老齡化以及患者對鞘內給藥作為一種臨床有效治療方法的認知不斷提高的推動。平均售價（ASP）預計將持續下降，這反映出在競爭激烈的市場中，價格壓力和產品差異化能力的不足。

整體市場成長仍微乎其微，預計預測期內銷售額僅略有成長。這反映出市場已趨於成熟，銷售量成長很大程度上被價格下跌、持續的法律和監管挑戰以及患者和保險公司持續高昂的成本所抵消。這些因素限制了該療法在那些與價格較低的替代療法相比具有明顯臨床優勢的患者群體之外的更廣泛應用。

市場概覽

全球鞘內幫浦市場致力於治療慢性頑固性疼痛和痙攣，其原理是將藥物直接輸送到脊髓腔內，使其與脊髓內的受體位點極為接近。這種接近性給藥方式相比口服或全身給藥，可顯著降低藥物劑量，從而獲得更持久、更穩定的治療效果，並最大限度地減少全身副作用。該市場已趨於成熟，成長基本持平。其成長受到許多因素的限制，包括高昂的治療成本、受法律法規過程而形成的激烈競爭環境，以及持續的價格壓力導致的平均售價（ASP）不斷下降。

需求主要來自小規模但穩定的患者群體，而全球人口老化又進一步推動了這項需求。隨著人口老化，需要慢性疼痛管理的患者人數不斷增加，使得鞘內治療成為這些患者的首選臨床治療方案。對於某些患者而言，鞘內治療與高劑量口服藥物相比，長期來看更具成本效益，尤其考慮到其可減少全身副作用和住院次數。然而，植入手術的高昂初始費用，以及持續的藥物補充和定期追蹤費用，限制了其在對成本敏感的地區和醫保覆蓋不足的患者中的應用。

儘管市場已趨於成熟，但技術進步仍在持續。可程式設計給藥系統如今能夠解決患者間和患者體內藥物反應的差異，而可變和穩態給藥模式的切換已成為主流平台的標準功能。奈米技術和電子技術的進步推動了泵浦組件的小型化，提高了患者的舒適度，並擴展了植入應用範圍。新產品電池壽命的延長減少了更換手術的頻率，凸顯了該療法的長期經濟可行性。 Flowonix Prometra II 就是一個特別值得關注的例子，其電池壽命超過 10 年。

法律和監管過程一直是該市場的顯著特徵，嚴重限制了市場信心和新參與企業的意願。市場領導者美敦力公司的SynchroMed II曾捲入集體訴訟和解，並多次被美國食品藥物管理局（FDA）召回。同時，Flowonix公司的Prometra II也面臨大規模召回，儘管規模較小。這些事件提高了市場准入所需的監管和責任門檻，削弱了醫生和患者對整個產品類型的信心，並阻礙了其成長潛力。

市場促進因素

患者意識和教育

對於某些慢性頑固性疼痛或痙攣患者，如果採用侵入性較小的療法無法有效控制疼痛，鞘內給藥可能是一種經濟有效且臨床效益顯著的治療選擇。由於此療法可將藥物直接輸送到脊髓受體附近，因此與口服給藥相比，其療效往往更持久，全身副作用的發生率也更低。提高患者對這些臨床益處的認知，並對醫生進行關於患者選擇標準和潛在併發症的全面培訓，將有助於加速該療法在適宜人群中的應用。隨著全球人口老化，需要治療慢性疼痛的患者數量不斷增加，預計在預測期內，鞘內治療的患者群體將持續擴大，即使在市場基本持平的情況下，也能保持穩定的最低銷售量。

技術進步

• 可程式設計藥物輸送系統的進步提高了鞘內幫浦的療效和臨床柔軟性，使臨床醫生能夠根據患者的個體差異調整輸注速率和給藥模式。透過控制單元在可變和穩態藥物傳輸模式之間切換，現已成為主流平台的標準功能。奈米技術和電子技術的創新實現了小型化，提高了患者的舒適度，並擴大了適合植入的患者群體。電池壽命的延長是一項特別重要的進步。 Flowonix Prometra II 的電池壽命超過 10 年，減少了更換手術的頻率，降低了長期治療成本。在脊髓和薦椎神經刺激中已得到驗證的可充電系統技術，目前也在探索將其應用於鞘內泵，可充電配置有望進一步延長設備壽命並降低整體擁有成本。

市場限制

價格和持續治療費用

與口服藥物等非手術治療方法相比，鞘內幫浦治療的費用要高得多。根據製造商和是否需要對設備維修，泵浦需要每4到8年進行一次手術更換，並且必須使用製造商指定的補充包來補充藥物，這導致整個治療期間持續產生費用。患者通常需要每6週到6個月就診一次以補充泵內藥物，這增加了整個治療期間的累積醫療費用負擔。初始植入費用、定期設備更換、持續的藥物補充和門診費用加起來，使得鞘內泵治療的長期成本遠高於非手術鎮痛方法。這種高昂的費用負擔導致一些患者和醫療機構選擇費用較低的替代療法，從而限制了鞘內泵治療的普及，並在對成本敏感的支付環境下抑制了其市場價值成長。

功能障礙和法律問題

鞘內泵市場受到與器械相關的法律和監管事件的嚴重影響，這些事件削弱了市場信心，阻礙了新進入者。美敦力公司的SynchroMed II曾面臨集體訴訟，並於2021年以3,500萬美元達成和解。 2019年，美國食品藥物管理局（FDA）發布了一項一級召回令，認定11,299台SynchroMed II器材可能有缺陷。 FDA先前也曾實施一項同意協議，限制SynchroMed II的銷售，僅限於醫生認為具有醫療必要性的病例，但該協議已於2017年解除。 Flowonics公司的Prometra II也面臨類似的情況，儘管小規模，並捲入了另外13起FDA二級召回事件。這些事件的累積導致市場領先產品的責任風險增加，限制了新進入者，並降低了臨床醫生、患者和保險公司對該類器械安全性和可靠性的信心，從而抑制了市場成長。

目錄

調查方法

• 第一步：專案啟動與團隊組建
• 步驟二：資料系統開發與二次調查實施
• 步驟三：準備面試設計問卷
• 第四步：進行初步調查
• 第五步：調查分析：基準估計
• 第六步：市場預測與分析
• 第七步：辨識策略機遇
• 步驟 8：最終確認和市場公告
• 步驟九：客戶回饋與市場監測

全球關稅的影響

鞘內幫浦市場

• 執行摘要
  • 全球鞘內幫浦市場概覽
  • 競爭分析
  • 涵蓋的治療
  • 目標市場
  • 目標區域
• 介紹
• 調查方法的數量
• 市場分析與預測
• 促進因素和抑制因素
  • 市場促進因素
  • 市場限制因素
• 競爭對手市佔率分析

附錄

The global intrathecal pump market was valued at $350 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 0.4%, reaching approximately $360 million by 2032.

This report covers intrathecal pumps used in the delivery of medication directly to the intrathecal space for the management of chronic, refractory pain and spasticity. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

The intrathecal pump market is expected to demonstrate modest growth over the forecast period, driven by gradual increases in unit sales supported by aging demographics and growing patient awareness of intrathecal drug delivery as a clinically effective therapy for selected patients. ASPs are projected to decline consistently, reflecting pricing pressures and limited product differentiation in a concentrated competitive field.

Overall market value growth remains minimal, with revenue increasing only slightly over the forecast period. This reflects a mature market where volume growth is largely offset by declining prices, ongoing legal and regulatory challenges, and a high ongoing cost burden for patients and payers that limits broader adoption beyond those for whom the therapy provides clear clinical advantages over less expensive alternatives.

Market Overview

The global intrathecal pump market addresses the management of chronic refractory pain and spasticity through direct delivery of medication to the intrathecal space, in close proximity to receptor sites in the spinal cord. This proximity allows for significantly lower drug doses compared to oral or systemic administration, reducing systemic side effects while achieving a therapeutic effect that tends to last longer and remain more consistent. The market is mature and near-flat, with growth constrained by high treatment costs, a concentrated competitive field shaped by legal and regulatory history, and an ASP environment eroding under sustained pricing pressure.

Demand is defined by a modest but stable patient base driven by the aging global population, which increases the number of patients with chronic pain management needs for whom intrathecal therapy provides a preferred clinical option. The therapy can be cost-effective over the long term for selected patients relative to high-dose oral regimens, particularly when accounting for reductions in systemic side effects and hospitalizations. However, the high upfront cost of implantation and the ongoing costs of drug refills and regular physician visits limit adoption in cost-sensitive environments and among patients without sufficient payer coverage.

Technological advancement has continued despite market maturity. Programmable delivery systems now address intra- and inter-patient variability in drug response, and variable and constant medication delivery mode switching is standard across leading platforms. Miniaturization of pump components, driven by advances in nanotechnology and electronics, is improving patient comfort and implant eligibility. Extended battery life in newer products is reducing replacement surgery frequency and supporting the long-term economic case for the therapy, most notably in the Flowonix Prometra II, which offers more than 10 years of battery life.

Legal and regulatory history has been a defining feature of this market and has materially constrained market confidence and new entrant appetite. The leading product, Medtronic's SynchroMed II, has been the subject of a class action lawsuit settlement and multiple FDA recalls, while the Flowonix Prometra II has faced a smaller but meaningful set of recall events. These events have raised the regulatory and liability threshold for market participation and suppressed growth potential by limiting physician and patient confidence in the broader product category.

Market Drivers

Patient Awareness and Education

Intrathecal drug delivery can be a cost-effective and clinically beneficial treatment for selected patients with chronic refractory pain or spasticity who have not achieved adequate control through less invasive approaches. Because the therapy delivers medication directly near receptor sites in the spinal cord, the therapeutic effect tends to last longer and the rate of systemic side effects is reduced compared to oral drug administration. Greater patient awareness of these clinical advantages, combined with intensive physician training in patient selection criteria and potential complications, can drive broader adoption among appropriate candidates. The aging global demographic is expanding the number of patients with chronic pain management needs, providing a growing patient base for intrathecal therapy over the forecast period and sustaining a stable volume floor even in a near-flat market environment.

Technological Advancements

• Advances in programmable drug delivery systems have improved both the efficacy and the clinical flexibility of intrathecal pumps, allowing clinicians to tailor infusion rates and delivery patterns to individual patient variability. Variable and constant medication delivery mode switching via a control unit is now a standard feature across leading platforms. Miniaturization driven by nanotechnology and electronics innovation is improving patient comfort and expanding the eligible implant population. Extended battery life is a particularly significant development: the Flowonix Prometra II offers more than 10 years of battery life, reducing replacement surgery frequency and lowering the long-term cost burden of the therapy. Rechargeable system technology, proven in spinal cord stimulation and sacral nerve stimulation, is also being evaluated for application to intrathecal pumps, with rechargeable configurations representing a potential pathway for further extending device longevity and reducing total cost of ownership.

Market Limiters

Pricing and Ongoing Treatment Costs

Intrathecal pump therapy is a considerably more expensive treatment option than non-surgical alternatives such as oral pharmaceuticals. Pumps require surgical replacement every four to eight years depending on the manufacturer and whether device revision is necessary, and drugs must be refilled using proprietary manufacturer refill kits that generate an ongoing cost throughout the duration of therapy. Patients typically require physician visits every six weeks to six months for pump refills, adding to the cumulative cost of care over the life of the therapy. The combination of upfront implantation costs, periodic device replacement, and ongoing refill and visit expenses makes intrathecal therapy significantly more expensive over time than non-surgical pain management approaches. This cost burden leads some patients and healthcare facilities to choose less expensive alternatives, limiting the breadth of adoption and constraining market value growth in cost-sensitive payer environments.

Malfunctions and Legal Issues

The intrathecal pump market has been significantly affected by device-related legal and regulatory events that have damaged market confidence and deterred new entry. Medtronic's SynchroMed II faced a class action lawsuit that was settled for $35 million in 2021. A 2019 Class I FDA recall identified 11,299 SynchroMed II devices as potentially defective, and the FDA had previously imposed a consent agreement that limited SynchroMed II sales to only those cases where a physician deemed it medically necessary, which was lifted in 2017. Flowonix's Prometra II has also faced similar issues on a smaller scale, with involvement in 13 additional Class II FDA recalls. The cumulative effect of these events has raised liability concerns for the market's leading products, limited new competitor entry, and suppressed market growth by reducing the confidence of clinicians, patients, and payers in the safety and reliability of the device category.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neuromodulation device industry leaders and implanting physicians, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals, ambulatory surgery centers, and pain management specialty clinics.

Markets Covered and Segmentation

• The intrathecal pump market is analyzed as a unified segment, assessed by procedure volume, unit volume, ASP, and market value with historical and forecast data provided:
• Intrathecal Pumps

Competitive Analysis

Medtronic was the leader in the global intrathecal pump market in 2025. The company competes through its SynchroMed II intrathecal drug delivery system, the most widely used and clinically established product in the segment. The SynchroMed II's long commercial track record and deep physician familiarity support Medtronic's market leadership despite the legal and regulatory history associated with the device. The company's commercial infrastructure, clinical support programs, and extensive physician training investment in intrathecal drug delivery reinforce its dominant position in a concentrated competitive field with limited new entry.

Flowonix held the second-leading position in the intrathecal pump market in 2025 through its Prometra intrathecal drug delivery system, including the Prometra II, which offers more than 10 years of battery life. This extended longevity represents a meaningful clinical and economic advantage for patients seeking to minimize the frequency of replacement surgeries and the associated cost and procedural risk. Flowonix's focus on the intrathecal pump segment and its emphasis on product longevity position it as the primary alternative to Medtronic's platform, despite having faced its own regulatory and recall events related to the Prometra II.

Tricumed held the third-leading position in the global intrathecal pump market in 2025 through its Siromedes intrathecal pump system. The company's presence provides an additional competitive option for physicians and healthcare systems seeking alternatives to the two primary market participants. Tricumed's position reflects the limited competitive diversity in a segment where the legal and regulatory burden of market entry has discouraged broader participation and where the two leading products have established deep clinical familiarity among the implanting physician community.

Technology and Practice Trends

• Programmable delivery systems: Advances in programmable drug delivery allow clinicians to customize infusion rates and patterns to individual patient variability, improving therapy precision and therapeutic consistency across diverse patient populations.
• Variable and constant delivery mode switching: Mode-switching capability via a control unit is now standard across leading intrathecal pump platforms, giving clinicians greater flexibility in managing therapy for patients with changing pain profiles or drug response patterns.
• Device miniaturization: Ongoing reductions in pump size driven by advances in nanotechnology and electronics are improving patient comfort and expanding the range of patients who are suitable candidates for intrathecal pump implantation.
• Extended battery life: The Prometra II's more than 10-year battery life significantly reduces the frequency of replacement surgery and lowers total therapy costs over time, strengthening the economic case for intrathecal drug delivery in eligible patients.
• Rechargeable system development: Rechargeable technology proven in SCS and sacral nerve stimulation systems is being evaluated for application to intrathecal pumps, representing a potential pathway to further reduce replacement frequency and long-term cost of ownership.
• Pharmacological advances: Continued development of intrathecal drug formulations and delivery protocols is improving therapy safety and efficacy, supporting physician confidence and expanding patient eligibility criteria over the forecast period.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• What is the true size and near-term growth trajectory of the global intrathecal pump market, and how is the interplay between modest unit volume growth and consistent ASP decline shaping net revenue outcomes through 2032?
• How are pricing pressures and limited product differentiation driving ASP erosion, and what are the commercial implications for the three primary market participants?
• What is the cumulative impact of device recalls, class action settlements, and FDA regulatory actions on physician prescribing behavior, market confidence, and new entrant appetite?
• How are advances in battery life, device miniaturization, and programmable delivery modes improving the clinical and economic case for intrathecal therapy, and what patients benefit most?
• Which companies lead the market and how are they differentiating their platforms in a near-flat, concentrated competitive environment with limited new entry?
• How are aging demographics and growing patient awareness sustaining volume demand in a near-flat market, and which geographies offer the most meaningful incremental growth opportunity?
• How do the ongoing costs of refills, replacement procedures, and regular physician visits affect payer coverage decisions and patient access to intrathecal drug delivery therapy?
• What are the key risks to market stability, including further regulatory actions, device safety events, and sustained competition from non-surgical chronic pain management alternatives?

The Global Intrathecal Pump Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to understand the structure and dynamics of a mature near-flat market, benchmark competitors, and identify the clinical and commercial conditions under which intrathecal therapy maintains and extends its patient base over the forecast period.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Intrathecal Pump Market

• 14.1 Executive Summary
  • 14.1.1 Global Intrathecal Pump Market Overview
  • 14.1.2 Competitive Analysis
  • 14.1.3 Procedures Included
  • 14.1.4 Markets Included
  • 14.1.5 Regions Included
• 14.2 Introduction
• 14.3 Procedure Numbers
• 14.4 Market Analysis And Forecast
• 14.5 Drivers And Limiters
  • 14.5.1 Market Drivers
  • 14.5.2 Market Limiters
• 14.6 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 14-1: Intrathecal Pump Market, Global, 2025 & 2032
• Chart 14-2: Intrathecal Pump Procedures, Global, 2025
• Chart 14-3: Intrathecal Pump Procedures by Region, Global, 2022 - 2032
• Chart 14-4: Intrathecal Pump Market, Global, 2022 - 2032
• Chart 14-5: Leading Competitors, Intrathecal Pump Market, Global, 2025

LIST OF FIGURES

• Figure 14-1: Intrathecal Pump Procedures Covered
• Figure 14-2: Intrathecal Pump Markets Covered
• Figure 14-3: Intrathecal Pump Regions Covered, Global (1 of 2)
• Figure 14-4: Intrathecal Pump Regions Covered, Global (2 of 2)
• Figure 14-5: Total Intrathecal Pump Procedures, Global, 2022 - 2032
• Figure 14-6: Intrathecal Pump Procedures by Region, Global, 2022 - 2032
• Figure 14-7: Intrathecal Pump Procedures by Country, North America, 2022 - 2032
• Figure 14-8: Intrathecal Pump Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 14-9: Intrathecal Pump Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 14-10: Intrathecal Pump Procedures by Country, Western Europe, 2022 - 2032
• Figure 14-11: Intrathecal Pump Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 14-12: Intrathecal Pump Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 14-13: Intrathecal Pump Procedures by Country, Middle East, 2022 - 2032
• Figure 14-14: Intrathecal Pump Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 14-15: Intrathecal Pump Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 14-16: Intrathecal Pump Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 14-17: Intrathecal Pump Procedures by Country, Africa, 2022 - 2032
• Figure 14-18: Intrathecal Pump Market, Global, 2022 - 2032
• Figure 14-19: Units Sold by Region, Intrathecal Pump Market, Global, 2022 - 2032
• Figure 14-20: Average Selling Price by Region, Intrathecal Pump Market, Global, 2022 - 2032 (US$)
• Figure 14-21: Market Value by Region, Intrathecal Pump Market, Global, 2022 - 2032 (US$M)
• Figure 14-22: Leading Competitors, Intrathecal Pump Market, Global, 2025